Toxicology – HIV Protease Inhibitors

Core Concept

HIV protease inhibitors (PIs) are antiretroviral drugs that inhibit the viral protease required for maturation of infectious HIV particles.

Older agents include:

• Ritonavir
• Indinavir
• Saquinavir

Other important PIs include:

• Darunavir
• Atazanavir
• Lopinavir
• Fosamprenavir

Some older agents such as indinavir and saquinavir are now rarely used in contemporary HIV treatment.

Acute isolated PI overdose is usually mild to moderate, with GI symptoms predominating. More clinically important toxicity often results from:

• Drug–drug interactions
• Hepatic dysfunction
• Chronic metabolic effects
• Agent-specific cardiac toxicity
• Renal complications
• Toxicity of another drug whose concentration has been increased by a pharmacokinetic booster

There is no specific antidote for PI overdose.

Mechanism

HIV initially produces large viral polyproteins.

HIV protease normally cleaves these precursor proteins into functional viral components.

Protease inhibitors block this process:

Protease inhibition → failure of viral protein processing → immature, noninfectious viral particles

They are generally administered as part of combination antiretroviral therapy rather than alone.

Pharmacokinetic Boosting

A major modern concept is the use of pharmacokinetic boosters.

Ritonavir

At low doses, ritonavir is commonly used primarily to inhibit drug metabolism and increase exposure to another PI.

Cobicistat

Cobicistat is another commonly used pharmacokinetic enhancer, although it has no useful anti-HIV activity by itself.

This makes drug interactions one of the most important clinical issues in PI toxicity.

Ritonavir and CYP3A

Ritonavir is a potent inhibitor of CYP3A and several drug transport pathways.

It can dramatically increase concentrations of susceptible medications.

Therefore, in a patient taking ritonavir, toxicity may arise not from ritonavir itself but from accumulation of another medication.

Drug Interactions – Major Toxicology Issue

Potentially important interacting drug groups include:

• Certain sedatives
• Opioids
• Antiarrhythmics
• Calcium-channel blockers
• Some statins
• Corticosteroids
• Anticoagulants
• Antiseizure medications
• Immunosuppressants
• Antimicrobials
• Other antiretroviral drugs

The exact interaction depends on the specific PI and accompanying medication.

Interaction Pattern

A useful approach is:

PI/booster + CYP3A substrate → reduced metabolism → increased substrate concentration → secondary toxicity

Possible secondary syndromes include:

• Excessive sedation
• Respiratory depression
• Hypotension
• Bradycardia
• Dysrhythmia
• Bleeding
• Myopathy/rhabdomyolysis
• Endocrine abnormalities

Ritonavir and Corticosteroids

An important modern interaction involves corticosteroids metabolized through CYP3A.

Ritonavir or cobicistat can markedly increase systemic corticosteroid exposure.

This can cause:

• Iatrogenic Cushing syndrome
• Adrenal suppression
• Metabolic complications

This interaction can occur even with some inhaled, injected, or intranasal corticosteroids.

Ritonavir and Statins

Some statins depend heavily on CYP3A metabolism.

Markedly increased exposure can cause:

Myopathy → rhabdomyolysis → hyperkalemia/AKI

Not every statin has the same interaction potential, so drug-specific interaction checking is required.

Rifampin Interaction – Correction

The older source suggests rifampin may increase PI concentrations.

This is generally backwards.

Rifampin is a potent enzyme inducer and can markedly reduce concentrations of many protease inhibitors.

This can result in:

• Loss of antiviral efficacy
• Virologic failure
• Resistance concerns

Many rifampin–PI combinations are therefore contraindicated or require an alternative regimen.

Acute Overdose

Isolated oral PI overdose most commonly causes:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Headache
• Dizziness

Serious toxicity from a single isolated ingestion is uncommon, although the specific agent, formulation, comorbidities, and coingestants matter.

1. Gastrointestinal Toxicity

GI adverse effects are common during both therapeutic use and excessive exposure.

Possible symptoms include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort
• Reduced appetite

Severe vomiting or diarrhea can produce:

• Dehydration
• Electrolyte abnormalities
• AKI

2. Hepatotoxicity

Protease inhibitors can produce elevations in liver enzymes and, less commonly, clinically significant hepatic injury.

Risk may be increased by:

• Preexisting liver disease
• Viral hepatitis coinfection
• Other hepatotoxic medications
• Complex multidrug therapy

Evaluation of significant toxicity may include:

• AST/ALT
• Bilirubin
• Alkaline phosphatase
• Coagulation studies if severe

3. Cardiac Toxicity

Cardiac electrophysiologic effects vary substantially between agents.

Potential abnormalities include:

• PR prolongation
• QT prolongation
• Bradyarrhythmia
• Ventricular dysrhythmia

These are not uniform class effects.

Atazanavir

Atazanavir can produce PR-interval prolongation and AV conduction abnormalities.

It also commonly causes indirect hyperbilirubinemia during therapy.

Saquinavir

Saquinavir has been associated with both:

• QT prolongation
• PR prolongation

Its use has declined considerably.

A significant overdose or interacting-drug exposure warrants ECG assessment.

ECG

Obtain an ECG when there is:

• Significant overdose
• Syncope
• Palpitations
• Bradycardia
• Hypotension
• Known QT/PR-active PI
• Other QT-prolonging drugs
• Significant electrolyte disturbance

Routine prolonged cardiac monitoring is unnecessary after every small asymptomatic exposure.

4. Renal Toxicity

The older source incorrectly attributes a common stone risk to ritonavir.

The classic PI associated with nephrolithiasis is indinavir.

Indinavir Nephrolithiasis

Indinavir can crystallize in urine and cause:

• Flank pain
• Hematuria
• Dysuria
• Crystalluria
• Nephrolithiasis
• Obstructive uropathy
• AKI

Adequate hydration during therapeutic use reduces risk.

Atazanavir can also rarely contribute to urinary calculi.

Cobicistat and Creatinine

Although not itself a protease inhibitor, cobicistat is frequently encountered with modern PI regimens.

It can inhibit tubular secretion of creatinine.

Therefore:

Serum creatinine may rise without a true reduction in glomerular filtration.

As with trimethoprim, this laboratory effect must be distinguished from genuine AKI.

5. Metabolic Toxicity

Long-term PI therapy can contribute to:

• Insulin resistance
• Hyperglycemia
• New or worsening diabetes
• Dyslipidemia
• Altered body-fat distribution

These are primarily chronic treatment effects, not characteristic findings after a single acute overdose.

Lipodystrophy

Older PI-containing antiretroviral regimens were particularly associated with metabolic and body-composition changes.

Possible findings included:

• Peripheral fat loss
• Central fat accumulation
• Dyslipidemia
• Insulin resistance

Modern antiretroviral regimens have substantially changed this toxicity profile.

6. Hyperbilirubinemia

Atazanavir inhibits bilirubin conjugation and can produce:

• Elevated unconjugated bilirubin
• Scleral icterus
• Jaundice

This can occur without significant hepatocellular injury.

Therefore:

Jaundice during atazanavir therapy does not automatically mean hepatitis.

Liver enzymes and the bilirubin pattern help distinguish the two.

7. Pancreatitis

Pancreatitis has occasionally been reported during antiretroviral therapy.

However, causation may be difficult to assign because patients often receive several medications with overlapping metabolic effects.

Symptoms include:

• Epigastric pain
• Nausea/vomiting
• Pain radiating to the back

Lipase is generally preferred over relying on amylase alone when pancreatitis is suspected.

8. Neurologic Effects

Possible adverse effects include:

• Headache
• Dizziness
• Paresthesias
• Taste disturbance

Severe:

• Confusion
• Seizures
• Coma

are not typical findings of uncomplicated isolated PI overdose.

When they occur, evaluate carefully for:

• Coingestants
• Drug interactions
• Metabolic disturbances
• CNS infection
• Other neurologic disease

The older source overstates peripheral neuropathy as a defining PI class toxicity.

9. Hematologic Effects

Cytopenias may occur in patients receiving HIV therapy, but attribution is often complicated by:

• HIV itself
• Opportunistic infections
• Other antiretroviral agents
• Bone-marrow suppressive medications
• Nutritional disease

CBC testing should therefore be clinically directed rather than assuming marrow suppression is a characteristic acute PI toxidrome.

Diagnosis

Determine:

• Exact PI
• Whether ritonavir or cobicistat is present
• Amount and timing
• Acute vs chronic exposure
• Complete medication list
• Renal function
• Hepatic function
• Coingestants

Because interactions are so important, medication reconciliation is often more informative than the PI dose alone.

Combination Products

Modern antiretroviral therapy frequently uses fixed-dose combinations.

Always identify every active ingredient.

Toxicity attributed to a “protease inhibitor tablet” may actually arise from:

• Another antiretroviral
• Pharmacokinetic booster
• Interacting medication
• Coingestant

Laboratory Evaluation

Small asymptomatic isolated exposures may require no laboratory investigation.

For symptomatic or clinically significant exposures, consider:

• Glucose
• Electrolytes
• BUN/creatinine
• Liver tests

Depending on presentation:

• CBC
• Bilirubin fractionation
• Lipase
• CK
• Urinalysis
• Potassium
• Magnesium

Rhabdomyolysis

If an interacting medication such as a susceptible statin is involved, assess for:

• Muscle pain
• Weakness
• Dark urine
• Elevated CK
• Hyperkalemia
• AKI

This represents interaction-mediated toxicity, not necessarily direct PI muscle toxicity.

Serum Protease-Inhibitor Levels

Routine serum PI concentrations are generally not useful in acute poisoning.

Treatment is based on:

• Symptoms
• ECG
• Organ function
• Identification of interacting drugs

Initial Management

General approach:

Airway/breathing → circulation → exact drug/formulation → complete medication reconciliation → ECG when indicated → renal/hepatic/metabolic assessment → supportive care

Most isolated acute ingestions require only symptomatic management.

GI Decontamination

Do not induce vomiting.

Ipecac has no role.

Routine gastric lavage is obsolete.

Activated charcoal may occasionally be considered after a substantial recent ingestion when:

• The exposure is clinically important
• The drug is adsorbable
• Airway protection is adequate
• Aspiration risk is acceptable

Most small uncomplicated exposures need no decontamination.

Hypotension

Significant hypotension is unusual after isolated PI ingestion.

If present, investigate:

• Dehydration
• Interacting cardiovascular medications
• Dysrhythmia
• Sepsis
• Anaphylaxis
• Coingestants

Treat appropriate volume depletion with isotonic crystalloid.

Persistent vasodilatory shock generally favors norepinephrine rather than a routine dopamine-first strategy.

Trendelenburg positioning is outdated.

Seizures

Seizures are unusual in uncomplicated PI poisoning.

If they occur:

• Consider coingestants and metabolic causes
• Check glucose and electrolytes
• Treat hypoxia

Benzodiazepines are first-line for toxicologic seizures.

Persistent seizures may require additional benzodiazepines, phenobarbital, or appropriate anesthetic therapy.

Dysrhythmias

Management is based on:

• Exact rhythm
• PR interval
• QRS duration
• QT interval
• Electrolytes
• Hemodynamic status
• Interacting medications

Correct potassium and magnesium abnormalities and discontinue relevant interacting/QT-active medications when possible.

There is no PI-specific universal antiarrhythmic regimen.

Enhanced Elimination

Hemodialysis generally has little role in removing protease inhibitors because many have:

• High protein binding
• Large distribution characteristics

Dialysis may still be required for conventional indications, such as severe renal failure or refractory electrolyte abnormalities.

No Specific Antidote

There is no specific antidote for PI overdose.

Treatment consists primarily of:

Supportive care + stopping further exposure + identifying interactions + treating secondary drug toxicity

Observation and Disposition

A universal observation period is unnecessary.

Disposition depends on:

• Exact PI
• Amount
• Symptoms
• ECG
• Coingestants
• Drug interactions
• Renal/hepatic function
• Clinical trajectory

Patients with a minor isolated exposure who remain well generally have a favorable course.

Admission

Hospitalization may be appropriate for:

• Persistent severe vomiting/dehydration
• AKI
• Significant hepatotoxicity
• Pancreatitis
• Rhabdomyolysis
• Significant PR/QT abnormality
• Dysrhythmia
• Hypotension
• Severe interaction-mediated toxicity
• Seizures or persistent altered mental status

ICU care is reserved for severe cardiovascular, respiratory, neurologic, or multiorgan toxicity.

Pregnancy and Breastfeeding

Historical FDA pregnancy letter categories are obsolete.

Antiretroviral therapy during pregnancy is important for both maternal health and prevention of perinatal HIV transmission.

Selection of a PI-containing regimen depends on:

• Current HIV treatment guidelines
• Resistance history
• Maternal viral suppression
• Drug interactions
• Pharmacokinetic changes during pregnancy
• Maternal and fetal safety data

The older blanket Category B description is therefore inadequate.

Safeguarding

Rigid historical age thresholds for assuming neglect, abuse, or intentional poisoning are outdated.

Pediatric exposure should instead be assessed according to:

• Developmental capability
• Medication accessibility
• Circumstances
• Consistency of history
• Recurrent unexplained exposure
• Broader safeguarding concerns

Prognosis

Most isolated acute PI overdoses have a favorable prognosis.

More serious outcomes are usually related to:

• Major drug interactions
• Cardiac conduction abnormalities
• Severe dehydration
• Renal injury
• Hepatic dysfunction
• Rhabdomyolysis
• Significant coingestants

Important Modernization of the Older Source

• Modern HIV treatment uses combination antiretroviral therapy; older agents such as indinavir and saquinavir are now rarely used.
• Acute isolated PI overdose is generally GI-predominant and relatively mild.
• Drug interactions are one of the major toxicologic concerns.
• Ritonavir is now commonly encountered as a pharmacokinetic booster because of potent CYP3A inhibition.
• Cobicistat is another important modern booster.
• Severe symptoms may reflect toxicity from an interacting drug rather than the PI itself.
• Ritonavir/cobicistat can markedly increase systemic exposure to certain corticosteroids, causing Cushing syndrome and adrenal suppression.
• Interactions with susceptible statins can produce rhabdomyolysis and AKI.
• Rifampin generally reduces, rather than increases, concentrations of many PIs through enzyme induction.
• Indinavir, not ritonavir, is the classic PI associated with nephrolithiasis/crystalluria.
• Atazanavir may cause benign unconjugated hyperbilirubinemia without hepatocellular injury.
• Cobicistat can increase creatinine by inhibiting tubular secretion without necessarily lowering true GFR.
• Cardiac toxicity is agent specific; atazanavir may prolong PR, while saquinavir has been associated with PR and QT abnormalities.
• Peripheral neuropathy is not a defining acute class toxicity.
• Severe CNS depression or seizures should trigger a search for coingestants, interactions, metabolic disease, or CNS pathology.
• Serum PI concentrations are generally not useful for acute management.
• Ipecac and routine gastric lavage are obsolete.
• Trendelenburg and routine dopamine-first shock management are outdated.
• Hemodialysis does not meaningfully enhance elimination of most PIs.
• Historical FDA pregnancy categories are obsolete.
• Fixed observation periods are unnecessary; disposition should be individualized.

Key Points

• Protease inhibitors block HIV protease and prevent viral maturation.
• Acute isolated overdose is usually mild and GI-predominant.
• Ritonavir is a potent pharmacokinetic booster and major source of drug interactions.
• Always review the entire medication list in suspected PI toxicity.
• Ritonavir/cobicistat + interacting drug can produce toxicity far more important than the PI exposure itself.
• Indinavir → crystalluria/nephrolithiasis/obstructive renal injury.
• Atazanavir → unconjugated hyperbilirubinemia and possible PR prolongation.
• Some older PIs can affect cardiac conduction and repolarization.
• There is no specific antidote.
• Most treatment consists of supportive care, recognition of interactions, and targeted management of complications.